龙源期刊网 http://www.qikan.com.cn
中药联合化疗治疗中晚期非小细胞肺癌的近期临床疗效分析
作者：周莉莉 张凤鸣 王红
来源：《世界中医药》2017年第08期
摘要 目的：研究分析中药联合化疗治疗中晚期非小细胞肺癌（Non-Small Lung Cancer，NSCLC）的近期临床疗效，以为临床应用提供依据。方法：随机选取2012年2月至2016年12月期间于我院进行治疗的中晚期NSCLC患者148例，并分为2组，联合组使用中药榄香烯治疗联合化疗，化疗组使用单纯化疗，经过3个周期的治疗后，观察比较2组患者的近期疗效，癌胚抗原（CEA）水平变化、生命质量及体力改善情况。结果：联合组治疗后，总有效50.0%，化疗组为28.38%（χ2=7.258，P
关键词 非小细胞肺癌；中药；化疗；近期疗效
Recent Analysis on Clinical Efficacy of Traditional Chinese Medicine with Chemotherapy in the Treatment of Non-small-cell Lung Cancer at Advanced Stage Zhou Lili， Zhang Fengming， Wang Hong
（Department of Oncology， Beijing Fengtai Hospital， Beijing 100070， China） Abstract Objective：To study the clinical efficacy of traditional Chinese medicine with chemotherapy in the treatment of non-small-cell lung cancer （NSCLC） at advanced stage in the treatment of non-small lung cancer （NSCLC） in Chinese traditional Chinese medicine， to provide references for clinical application.Methods：A total of 148 cases with advanced NSCLC treated in the hospital from February 2012 to December 2016 were selected and randomly divided into two groups. Patients in the treatment group were given elemene combined with chemotherapy， while patients in the chemotherapy group only received chemotherapy. After 3 courses of treatment， the curative effect and changes in carcinoembryonic antigen （CEA） level， quality of life and physical strength of the two groups were observed and compared.Results：The curative effect rate of the treatment group was 50.0% and the chemotherapy group was 28.38%. （χ2=7.258，P
Key Words Non-small-cell lung cancer； Traditional Chinese medicine ； Chemotherapy； Recent efficacy
中图分类号：R256.1；R730.59文献标识码：Adoi：10.3969/j.issn.1673-7202.2017.08.018 随着社会经济的发展、全球人口数量的增加、自然环境的恶化以及人口老龄化形式的严峻，现代人各类不良习惯的养成（如吸烟、熬夜、暴饮暴食等），和肺癌相关性死亡报道的案
